drugset / Trial / NCT04161066
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
Phase 1
Recruiting
10 enrolled
University of Wisconsin, Madison
Etheridge Foundation · collabHeffter Research Institute · collab
NaSingle-groupOpen-labelHealth-services research
Summary
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy. Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.
Timeline
- Start
- 2021-01-13
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | — | Oral |